The Wee1 inhibitor adavosertib was combined with olaparib for patients with PARPi-resistant ovarian cancer in the phase II EFFORT study, showing an overall RR of 29% in combination vs. 23% for adavosertib alone, and a median PFS of 6.8 months in combination vs. 5.5 months for adavosertib alone [50]. Here, WEE1 is linked to ovarian carcinoma.